Q-omics provides the consensus-scored TNNT2 profile across patient tissues and cancer cell-line models. TNNT2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TNNT2 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TNNT2 RNA expression shows 15,660 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where TNNT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNNT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNNT2 survival associations across molecular data types. TNNT2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNNT2 RNA expression–survival associations across cancer types. High TNNT2 expression shows unfavorable associations in KIRP, COAD, READ, THCA and LUAD, but favorable associations in DLBC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for TNNT2 RNA expression.
This table summarizes TNNT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TNNT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNNT2 shows lower tumor expression in KIRC, KIRP, BLCA and LUAD and higher tumor expression in COAD and THCA. The KIRC box plot shows higher TNNT2 RNA expression in normal versus tumor tissue (log2 FC = −2.930, t-test p < 0.001).
This table shows molecular features associated with TNNT2 in patient tissues and cancer cell lines. In patient samples, TNNT2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TNNT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
